ESMO24: Immunotherapy Plus Chemotherapy Improves Progression-Free Survival in Metastatic Anal Cancer
Anti-PD-1 immunotherapy retifanlimab plus standard of care chemotherapy demonstrate significantly longer median PFS vs standard of care for patients with squamous cell carcinoma of the anal canal. The combination might become a new standard of care for these patients.
